EUROGIN 2008 roadmap on cervical cancer prevention†
Article first published online: 11 JUN 2009
Copyright © 2009 UICC
International Journal of Cancer
Volume 125, Issue 10, pages 2246–2255, 15 November 2009
How to Cite
Franceschi, S., Cuzick, J., Herrero, R., Dillner, J. and Wheeler, C. M. (2009), EUROGIN 2008 roadmap on cervical cancer prevention. Int. J. Cancer, 125: 2246–2255. doi: 10.1002/ijc.24634
Conflicts of interest: Dr. C. Wheeler has received funding through her institution for equipment and reagents for HPV genotyping from Roche Molecular Systems and to conduct studies related to HPV vaccines from Merck and Co., Inc. and Glaxo SmithKline. Dr. J. Cuzick reports participation in Advisory Boards (GenProbe, GlaxoSmithKline, Roche); receipt of Research Grants (Qiagen, Roche, Gen Probe, Genomica, MTM) and participation in Speakers Bureau (Qiagen). Dr. R. Herrero is the co-principal investigator of the Costa Rica HPV vaccine trial, sponsored and funded by the United States National Cancer Institute (NCI) (contract N01-CP-11005), with funding support from the National Institutes of Health Office for Research on Women's Health, and conducted with support from the Ministry of Health of Costa Rica. Vaccine was provided for the Cosa Rica trial by GSK Biologicals, under a Clinical Trials Agreement with the NCI. GSK also provided support for aspects of the trial associated with regulatory submission needs of the company under FDA BB-IND 7920. The NCI and Costa Rica investigators are responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data, and are not funded by vaccine manufacturing companies. Dr. J. Dillner reports participation in Advisory Board (Merck & Co., Inc.); has acted as a consultant (Merck & Co., Inc.); receipt of Research Grants (Merck & Co., Inc.) and participation in a Steering Committee (Merck & Co., Inc.). Dr. S. Franceschi has no conflict of interest to declare.
- Issue published online: 18 SEP 2009
- Article first published online: 11 JUN 2009
- Manuscript Accepted: 26 MAY 2009
- Manuscript Received: 23 MAY 2009
- 1An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26( Suppl 10): K53–K61., , , .
- 2Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743–53., , , , , , , , , , , .
- 3The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861–8.
- 4WHO Strategic Advisory Group of Experts (SAGE). Meeting of the immunization Strategic Advisory Group of Experts, November 2008—conclusions and recommendations. Wkly Epidemiol Rec 2009; 84: 1–16.
- 5Health and economic implications of HPV vaccination in the United States. N Engl. J Med 2008; 359: 821–32., .
- 6Prophylactic HPV vaccines: New interventions for cancer control. Vaccine 2008; 26: 6244–57., .
- 7Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun. Dis. Intell 2008; 32: 457–61., , , , , , , , , .
- 8Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill 2008; 13(33):p ii: 18954., , , , , , .
- 9Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008; 26: 6529–41., , , , , .
- 10Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008; 26( Suppl 12): M17–M29., , , , , .
- 11EUROGIN 2007 roadmap—conclusion. Vaccine 2008; 26( Suppl 1): A28–A31., .
- 12Is viral status needed before vaccination?. Vaccine 2008; 26( Suppl 1): A12–A15., .
- 13Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198: 971–8., , , , , , , , .
- 14Age for HPV vaccination. Vaccine 2008; 26( Suppl 1): A7–11., .
- 15Safety, immunogenicity and efficacy of quadrivalent human papillomavirus types (6,11,16,18) recombinant vaccine in women aged 24–45 years: a randomised double-blind trial. Lancet 2009; 373: 1949–57., , , , , , , , , , , , , , , , , .
- 16Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161–70., , , , , , , , , , , , et al.
- 17The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199: 926–35., , , , , , , , , , , , et al.
- 18The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009; 199: 936–44., , , , , , , , , , , , et al.
- 19Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26( Suppl 1): A16–A23., .
- 20Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095–101., , , , , , , , , , .
- 21Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579–88., , , , , , , , .
- 22Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765–74., , , , , , , , , , , , et al.
- 23Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology—results from the Hammersmith study. Int J Cancer 2008; 122: 2294–300., , , , , , , , , , .
- 24Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764–72., , , , , , , , , , , , et al.
- 25Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589–97., , , , , , , , , , , , et al.
- 26Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754., , , , , , , , , , , , et al.
- 27Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004; 291: 2100–6., , , , , .
- 28Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337: a1284., , , , , , , .
- 29Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492–501., , , , , , , , , , , , et al.
- 30Re: a study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 938–9., .
- 31Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621–32., , , , , , .
- 32Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937–45., , , , , , , , , , , , et al.
- 33HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385–94., , , , , , , , , , , , et al.
- 34A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929–36., , , , , , , , , , , , et al.
- 35Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26( Suppl 11): L96–L107., , , , , , .
- 36Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 2008; 26( Suppl 11): L88–L95., , , , , , , , .
- 37Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26( Suppl 10): K29–K41., , , , , , , .
- 38Quality control for normal liquid based cytology: rescreening, high risk HPV targeted reviewing and/or high risk HPV detection? J Cell Mol Med, in press., , , , , .
- 39Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–27., , , , , , , .
- 40Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–8., , , , , , , , , , , , et al.
- 41Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571–83., , , , , , , , , , , , et al.
- 42Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005; 23: 3634–41., , , , , , , .
- 43Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007; 25: 3302–10., , , , , , , , , .
- 44Plant-based vaccines. Int J Parasitol 2003; 33: 479–93., .
- 45An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J 2009; 6: 2., , , , , , .
- 46Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 2008; 6: 427–41., , , , , , , .
- 47Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003; 77: 8702–11., , , , , , , .
- 48Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007; 88(Part 5): 1460–9., , , , , , , , .
- 49Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003; 77: 4635–45., , , , , , , , , , , .
- 50Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008; 105: 5850–5., , , , , , , , .
- 51Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009; 101: 782–92., , , , , , , .
- 52Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007; 81: 11585–92., , , , , , .
- 53Arrangement of L2 within the papillomavirus capsid. J Virol 2008; 82: 5190–7., , , , , , .
- 54Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 2008; 82: 4638–46., , , , .
- 55Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 2003; 77: 12961–7., , , , .
- 56Cleavage of the papillomavirus minor capsid protein. L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 2006; 103: 1522–7., , , .
- 57Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 2008; 80: 841–6., , , , .
- 58Development of an HPV vaccine for a broad spectrum of high-risk types. Hum Vaccin 2008; 5: 43–5., .
- 59Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000; 18: 2444–53., , , , , , .
- 60Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 2006; 72: 745–52., , , , , , , , .
- 61Construction of prophylactic human papillomavirus type 16 L1 capsid protein vaccine delivered by live attenuated Shigella flexneri strain sh42. Acta Biochim Biophys Sin (Shanghai). 2005; 37: 743–50., , , , , , .
- 62Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004; 78: 12901–9., , , , .
- 63Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009; 27: 3385–90., , , , , , .
- 64Measles virus. In: KnipeDM,HowleyPM, editors. Fields virology, 5th edn., vol. 2. Philadelphia: Lippincott, Williams, Wilkins, 2007. 1551–85..
- 65Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999; 30: 269–74., , , , .
- 66Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004; 16: 485–91., .
- 67Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2009; 27: 1040–9., , , , , , , , .
- 68Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther 2008; 7: 1329–35., , , , , , , , .
- 69Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006; 118: 3022–9., , , , , , .
- 70Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475–87., , , , , .
- 71CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441–6., , , , , , , , , , , .
- 72A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110(3 Suppl 1 ): S18–S25.
- 73Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40: 564–71., , , , , , , , , , .
- 74Burden of HPV in males: design of an efficacy trial of a prophylactic HPV 6/11/16/18 vaccine among men aged 16–26 years. EUROGIN 2008, Nice, France, 12–15 November 2008, Abstract SS 19–7..
- 75Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693–702., , , , , , , , , , , , et al.
- 76Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475–87., , , , , .
- 77Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007; 148: 199–207., , .
- 78International quality assurance of human papillomavirus testing. Cent Eur J Public Health 16: S16–S20, 2008., .
- 79WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24–25 January 2008, Geneva, Switzerland. Vaccine 2009; 27: 337–47., , .
- 80Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89: 88–93., , .